Literature DB >> 8632320

kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine.

T S Shippenberg1, A LeFevour, C Heidbreder.   

Abstract

A place preference conditioning procedure was used to examine the influence of kappa-opioid receptor ligands upon the development of sensitization to the conditioned rewarding effects of cocaine. Previous exposure to cocaine (10-20 mg/kg; i.p.; days 1-5) resulted in an enhancement of the conditioned rewarding effects of this agent, e.g., sensitization. Thus, doses of cocaine (5.0-10.0 mg/kg; i.p.) that failed to produce place preferences in control rats produced significant place preferences in cocaine-experienced animals. In animals that had received the kappa-agonist U50,488H (5.0 mg/kg; s.c.) in combination with the repeated cocaine treatment regimen, no enhancement of cocaine-induced place conditioning was seen. Similarly, the kappa-agonist U69593 administered on days 1 to 5 or only on days 3 to 5 of the cocaine treatment regimen prevented the enhanced response to cocaine. This effect occurred after either systemic (0.04-0.16 mg/kg; s.c.) or intracerebroventricular (1.0 mg) treatment and was abolished by the kappa-opioid receptor antagonist, nor-binaltorphimine. In contrast to its effects when administered in combination with cocaine, prior administration of U69593, alone, failed to modify the conditioned response to cocaine. Microdialysis studies revealed a marked elevation of extracellular dopamine levels within the ventral striatum after repeated cocaine administration. In animals that had received U69593 in combination with cocaine, no elevation of dopamine was seen. These data demonstrate that sensitization develops to the conditioned rewarding effects of cocaine and that the activation of central nervous system kappa-opioid receptors prevents the development of this phenomenon. An involvement of the mesolimbic dopamine system in mediating the interaction of kappa-agonists with cocaine is suggested.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  55 in total

1.  kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.

Authors:  F C Dalman; K L O'Malley
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

2.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

Review 3.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

4.  Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference.

Authors:  Jeffrey S Smith; Abigail G Schindler; Emma Martinelli; Richard M Gustin; Michael R Bruchas; Charles Chavkin
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

5.  κ-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance.

Authors:  Shanna L Resendez; Morgan Kuhnmuench; Tarin Krzywosinski; Brandon J Aragona
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

6.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

7.  The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors.

Authors:  Mark A Smith; Jennifer L Greene-Naples; Megan A Lyle; Jordan C Iordanou; Jennifer N Felder
Journal:  J Pharmacol Exp Ther       Date:  2009-04-29       Impact factor: 4.030

Review 8.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

9.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

10.  Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment.

Authors:  Jason J Paris; Kate J Reilley; Jay P McLaughlin
Journal:  J Addict Res Ther       Date:  2011-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.